PPARδ Agonist Compound II for Mitochondrial Myopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for primary mitochondrial myopathies, fatty acid oxidation disorders, glycogen storage diseases, muscular dystrophies, and other metabolic disorders lack effective therapies to improve mitochondrial function and patient outcomes.
Innovation Solution
Administration of the PPARδ agonist compound sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate (Compound II) to enhance fatty acid oxidation, mitochondrial biogenesis, and oxidative phosphorylation, thereby improving exercise tolerance and reducing symptoms in affected mammals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for primary mitochondrial myopathies and metabolic disorders, then current standard of care is maintained, but effective therapy to improve mitochondrial function and patient outcomes is lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PPARδ agonists to optimize their therapeutic properties. Compound II features specific structural modifications including a fluorophenyl group, morpholinoprop-1-yn-1-yl substituent, and allyl linkage that enhance binding affinity and selectivity for PPARδ, thereby improving mitochondrial function and patient outcomes in metabolic disorders
2Reliability
If PPARδ agonist Compound II is administered to enhance fatty acid oxidation and mitochondrial biogenesis, then exercise tolerance and mitochondrial function are improved, but the complexity of the chemical compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the complex PPARδ agonist molecule into distinct functional segments: a fluorophenyl group for receptor recognition, a morpholinoprop-1-yn-1-yl group for metabolic modulation, and an allyl-phenoxyacetic acid core structure. This modular architecture allows each segment to contribute specifically to the overall therapeutic effect while maintaining synthesizability
Solution Approach 2:
The patent applies composite materials by combining multiple chemical moieties with complementary functions into a single hybrid molecule. Compound II integrates aromatic rings, alkyne linkages, heterocyclic groups, and carboxylic acid derivatives to create a composite molecular structure that achieves enhanced PPARδ agonism and improved clinical outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound II increases oxidative phosphorylation, improves exercise tolerance, and reduces symptoms such as fatigue and muscle weakness in mammals with primary mitochondrial myopathies and other metabolic disorders by promoting mitochondrial biogenesis and fatty acid oxidation.
Implementation Method 1
PPARδ, a member of the nuclear regulatory superfamily of ligand-activating transcriptional regulators, is expressed throughout the body. PPARδ agonists induce genes related to fatty acid oxidation and mitochondrial biogenesis.
Implementation Method 2
Compound II increases oxidative phosphorylation, improves exercise tolerance, and reduces symptoms such as fatigue and muscle weakness in mammals with primary mitochondrial myopathies and other metabolic disorders
Implementation Method 3
PPARδ agonists induce genes related to fatty acid oxidation and mitochondrial biogenesis
Data Source
AI summary
Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPARδ agonist compound.